developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease
Welcome to BioVex

Welcome to BioVex
Who we are.

BioVex is a privately held biotechnology company based in Woburn, Mass. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

The Company’s lead product, OncoVEXGM-CSF is a first in class oncolytic vaccine. OncoVEXGM-CSF is currently being evaluated in a Phase 3 multi-national study in metastatic melanoma and a Phase 3 study in head & neck cancer is scheduled to commence in the second half of 2010. BioVex believes OncoVEXGM-CSF has the potential to become a leading standard of care in the treatment of many solid tumors based on the strength of clinical data so far generated coupled with the relatively benign side effect profile noted to date.

Previous clinical trials have enrolled patients with breast cancer, melanoma, head and neck cancer and pancreatic cancer, with indications of clinical activity being observed in each. The Company is currently conducting a Phase 3 study in metastatic melanoma (the OPTiM study) following achieving an unprecedented proportion of durable complete remissions in a Phase 2 study using OncoVEXGM-CSF as a stand alone therapy.

The Company has recently also commenced clinical testing in the UK with ImmunoVEXHSV2 its vaccine candidate for the prevention and potentially the treatment of genital herpes.

BioVex closed a $70m funding round representing the second largest venture capital raise in the biotech sector in 2009.

 

Corporate Presentation pdf: OncoVEX clinical trials

View the trial results

External link

Latest News

August 2, 2010
BioVex announces publication of head and neck cancer clinical trial results with OncoVEXGM-CSF in the journal Clinical Cancer Research

BoiVex announces that the data from its completed Phase I/II clinical study of OncoVEXGM-CSF for the first line treatment of head and neck cancer is being published today in Clinical Cancer Research, an ASCO publication.
+ press release

July 22, 2010
BioVex appoints Ex Roche Oncology Head, Kapil Dhingra, to the Board of Directors

BioVex Inc announced today that it has appointed Dr Kapil Dhingra to the Board of Directors as a Non-Executive.
+ press release

July 1, 2010
BioVex appoints Steven Kelly as Chief Commercial Officer

BioVex announced today that that it has appointed Steven Kelly as Chief Commercial Officer. With the assistance of Mr. Tim Hanke, VP Commercial Operations, Mr. Kelly will have overall responsibility for the Company’s commercial activities.
+ press release

 

 

Legal Notice | SiteMap | Contact Us | Copyright © BioVex 2010